Business Context and Reporting Period
This Form 8-K was filed by Capricor Therapeutics, Inc. on November 13, 2019. The report addresses a regulatory event concerning the company's listing status on The Nasdaq Capital Market.
Key Financial Metrics
The filing references the company's Form 10-Q for the period ended September 30, 2019, which demonstrated stockholders' equity of $3.57 million. No other financial metrics, including revenue, profit, cash flow, or debt levels, are provided in this specific document.
Material Changes
The primary material event is the resolution of a listing deficiency. The company received notification from the Nasdaq Listings Qualification Department that it has regained compliance with Listing Rule 5550(b)(1). Consequently, the matter regarding the company's listing status is now closed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of new risks or contingencies beyond the resolution of the Nasdaq compliance issue.
Investor Verification Checklist
- Verify the company's continued compliance with Nasdaq Listing Rule 5550(b)(1) in subsequent filings.
- Review the full Form 10-Q for the period ended September 30, 2019, to analyze the $3.57 million stockholders' equity figure in context with other financial statements.
- Confirm the current trading status of the common stock (CAPR) on The Nasdaq Capital Market.